Q2 2015 13F Holders as of 6/30/2015
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
67
-
Total 13F shares, excl. options
-
10.6M
-
Shares change
-
+5.73M
-
Total reported value, excl. options
-
$109M
-
Value change
-
+$58.5M
-
Put/Call ratio
-
0.83
-
Number of buys
-
55
-
Number of sells
-
-11
-
Price
-
$10.29
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q2 2015
76 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q2 2015.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 67 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 10.6M shares
of 236M outstanding shares and own 4.47% of the company stock.
Largest 10 shareholders include EAGLE ASSET MANAGEMENT INC (2.43M shares), FMR LLC (1.97M shares), BlackRock Fund Advisors (990K shares), BALYASNY ASSET MANAGEMENT LLC (828K shares), VANGUARD GROUP INC (494K shares), Marshall Wace LLP (400K shares), RENAISSANCE TECHNOLOGIES LLC (381K shares), EMERALD MUTUAL FUND ADVISERS TRUST (306K shares), STATE STREET CORP (231K shares), and BOGLE INVESTMENT MANAGEMENT L P /DE/ (191K shares).
This table shows the top 67 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.